Synovial joint fluid cytokine levels in hip disease

Abe, Hirohito; Sakai, Takashi; Ando, Wataru; Takao, Masaki; Nishii, Takashi; Nakamura, N.; Hamasaki, Toshimitsu; Yoshikawa, Hideki; Sugano, Nobuhiko

doi:10.1093/rheumatology/ket334

Cited by 40 publications

(35 citation statements)

References 35 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The discrepancy between the results of the previous studies has been explained by loss of TNF-α activity during storage, presence of specific inhibitors in the SF, transient peaks in TNF-α activity during the disease, and different methods of sample preparation [21, 57, 58]. However, not detecting any TNF-α in our osteoarthritic dogs might also be explained by the chronicity of the disease, as the level of TNF-α has previously been reported to be higher in acute severe joint disease compared to joint disease in general [59], but conflicting findings have also been recently published [22, 60]. …”

Section: Discussionmentioning

confidence: 83%

The effect of intra-articular botulinum toxin A on substance P, prostaglandin E2, and tumor necrosis factor alpha in the canine osteoarthritic joint

et al. 2017

View full text Add to dashboard Cite

BackgroundRecently, intra-articular botulinum toxin A (IA BoNT A) has been shown to reduce joint pain in osteoarthritic dogs. Similar results have been reported in human patients with arthritis. However, the mechanism of the antinociceptive action of IA BoNT A is currently not known. The aim of this study was to explore this mechanism of action by investigating the effect of IA BoNT A on synovial fluid (SF) and serum substance P (SP), prostaglandin E2 (PGE2), and tumor necrosis factor alpha (TNF-α) in osteoarthritic dogs. Additionally, the aim was to compare SF SP and PGE2 between osteoarthritic and non-osteoarthritic joints, and investigate associations between SP, PGE2, osteoarthritic pain, and the signalment of dogs. Thirty-five dogs with chronic naturally occurring osteoarthritis and 13 non-osteoarthritic control dogs were included in the study. Osteoarthritic dogs received either IA BoNT A (n = 19) or IA placebo (n = 16). Serum and SF samples were collected and osteoarthritic pain was evaluated before (baseline) and 2 and 8 weeks after treatment. Osteoarthritic pain was assessed with force platform, Helsinki Chronic Pain Index, and joint palpation. Synovial fluid samples were obtained from control dogs after euthanasia. The change from baseline in SP and PGE2 concentration was compared between the IA BoNT A and placebo groups. The synovial fluid SP and PGE2 concentration was compared between osteoarthritic and control joints. Associations between SP, PGE2, osteoarthritic pain, and the signalment of dogs were evaluated.ResultsThere was no significant change from baseline in SP or PGE2 after IA BoNT A. Synovial fluid PGE2 was significantly higher in osteoarthritic compared to control joints. Synovial fluid PGE2 correlated with osteoarthritic pain. No associations were found between SP or PGE2 and the signalment of dogs. The concentration of TNF-α remained under the detection limit of the assay in all samples.ConclusionsThe results suggest that the antinociceptive effect of IA BoNT A in the joint might not be related to the inhibition of SP nor PGE2. Synovial fluid PGE2, but not SP, could be a marker for chronic osteoarthritis and pain in dogs.

show abstract

Section: Discussionmentioning

confidence: 83%

The effect of intra-articular botulinum toxin A on substance P, prostaglandin E2, and tumor necrosis factor alpha in the canine osteoarthritic joint

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Control [1,5,12,18,19,49]; atrophic versus hypertrophic in two studies [13,14]; and radiographic OA classification in five studies [6,23,42,47,48]. Two studies [15,20] analyzed minimum joint space width as a continuous variable relative to biomarker levels.…”

Section: Literature Searchmentioning

confidence: 99%

What Is the Utility of Biomarkers for Assessing the Pathophysiology of Hip Osteoarthritis? A Systematic Review

Nepple

Thomason

et al. 2015

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

show abstract

“…It has been shown that circulating levels of IL-6 are drastically increased during infections or in the contest of other inflammatory conditions, such as autoimmune rheumatic diseases 35,36. Patients with RA show elevated concentration of IL-6 levels both in the serum (ranging from 5 pg/mL to 200 pg/mL, with 1–16 pg/mL being the physiologic range in healthy people) and in the synovial fluid (about 100–1,000 fold higher than controls) 37–39. Serum levels of IL-6 in RA patients correlate with disease severity and radiological joint progression 40,41.…”

Section: Introductionmentioning

confidence: 99%

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis

Raimondo

Biggioggero

Crotti

et al. 2017

DDDT

View full text Add to dashboard Cite

In recent years the use of biotechnological agents has drastically revolutionized the therapeutic approach and the progression of rheumatoid arthritis (RA). In particular, interleukin-6 (IL-6) has been demonstrated as a pivotal cytokine in the pathogenesis of the disease by contributing to both the innate and the adaptive immune system perturbation, and to the production of acute-phase proteins involved in the systemic expression of the disorder. The first marketed IL-6 blocker was tocilizumab, a humanized anti-IL-6 receptor (anti-IL-6R) monoclonal antibody. The successful use of tocilizumab in RA has encouraged the development of other biologic agents specifically targeting the IL-6 pathway, either directed against IL-6 cytokine (sirukumab, olokizumab, and clazakizumab) or IL-6 receptor (sarilumab). One Phase II and six Phase III randomized controlled trials demonstrated a broad efficacy of sarilumab across all RA patient subtypes, ranging from methotrexate (MTX) to tumor necrosis factor inhibitor insufficient responders. In particular, sarilumab as monotherapy demonstrated a clear head-to-head superiority over adalimumab in MTX-intolerant subjects. In addition, compared with tocilizumab, sarilumab showed a similar safety profile with significantly higher affinity and longer half-life, responsible for a reduction of the frequency of administration (every other week instead weekly). All these aspects may be important in defining the strategy for positioning sarilumab in the treatment algorithm of RA. Indeed, observational data coming from post-marketing real-life studies may provide crucial additional information for better understanding the role of sarilumab in the management of the disease. This review summarizes both the biological role of IL-6 in RA and the clinical data available on sarilumab as an alternative therapeutic option in RA patients.

show abstract

Synovial joint fluid cytokine levels in hip disease

Abstract: IL-8 levels in RDC were higher than in the other hip diseases. The IL-8 level may reflect the aggressiveness of joint destruction in RDC, and IL-6 and TNF-α levels may also reflect ongoing destruction in OA and ON.

Cited by 40 publications

References 35 publications

The effect of intra-articular botulinum toxin A on substance P, prostaglandin E2, and tumor necrosis factor alpha in the canine osteoarthritic joint

The effect of intra-articular botulinum toxin A on substance P, prostaglandin E2, and tumor necrosis factor alpha in the canine osteoarthritic joint

What Is the Utility of Biomarkers for Assessing the Pathophysiology of Hip Osteoarthritis? A Systematic Review

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis

Contact Info

Product

Resources

About